Provenge News
Most Popular Provenge Story
Dendreon shares gyrate on Provenge panel rumor
Shares of Dendreon sank 5 percent in pre-market trading after investors got word of a note from Elliot Favus of Favus Institutional Research claiming that his firm had been in contact with physicians... Read more...
Latest Headlines
- March 2, 2010
- February 18, 2010
- November 2, 2009
- August 11, 2009
- April 29, 2009
- April 20, 2009
- April 17, 2009
- April 14, 2009
- August 13, 2008
- April 16, 2008
- February 1, 2008
- January 3, 2008
- October 23, 2007
- July 11, 2007
- June 27, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
